Drug intelligence / Profile preview

PSB128

Development stage: Unknown
Lead developer: Sound Biologics
Modality: Monoclonal Antibodies → Antibody-Based Therapeutics

Overview

PSB128 is a monoclonal antibody developed by Sound Biologics for the treatment of Alzheimer's disease and other neurological conditions. The therapeutic candidate is designed to target beta-amyloid (amyloid-β) plaques, a hallmark of Alzheimer's pathology, to facilitate their clearance and potentially slow the progression of neurodegeneration. According to company pipeline information, PSB128 is currently in Phase 1 clinical development, representing a key component of Sound Biologics' efforts to apply its biologics platform to central nervous system disorders.

Targets

Aβ (Amyloid-beta peptides and aggregates)

Beyond the preview

Go deeper on PSB128.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PSB128.

Explore the full profile